

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

PROFIT WARNING

This announcement is made by Sinopharm Tech Holdings Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on its preliminary review on the Group’s unaudited consolidated management accounts for the year ended 30 June 2026 (the “**Reporting Period**”) and information currently available, the Group is expected to record a loss attributable to owners of the Company between HK\$9 million and HK\$11 million for the Reporting Period, as compared with the loss attributable to owners of the Company of approximately HK\$0.8 million for the year ended 30 June 2025. The Board considered that the increase in the loss attributable to owners of the Company for the Reporting Period was mainly attributable to (i) a significant year-on-year decrease in revenue for the Group’s supply chain services business and (ii) an increase in selling and distribution expenses during the Reporting Period against the corresponding period in 2025 due to the increase in products promotion costs.

As at the date of this announcement, the Company is still in the course of finalising its annual results of the Group for the Reporting Period. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to the information currently available to the Company. Such information has neither been audited or reviewed by the auditors and audit committee of the Company and may be subject to change. Shareholders and potential investors shall refer to the annual results of the Group for the Reporting Period to be published on or around 24 September 2026.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
KWOK Shuk Yi
Executive Director

Hong Kong, 18 September 2026

As at the date of this announcement, the Board comprises Mr. CHIU Sin Nang Kenny and Ms. KWOK Shuk Yi as executive Directors, and Mr. LAU Fai Lawrence, Mr. HEUNG Pik Lun, Mr. DIU Peter and Mr. YU Ping Ming as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at <https://www.hkexnews.hk> for a minimum period of 7 days from the date of its publication and on the website of the Company at <http://www.sinopharmtech.com.hk>.